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Practical aspects of surgical treatment for prostate cancer
Patricia Tai1, Michael Crichlow2
This review summarizes the different surgical approaches for prostatectomy. Radical prostatectomy can be performed using a
perineal or retropubic approach. Walsh's landmark studies on pelvic and prostatic anatomy and the resultant surgical
implications have increased the popularity of radical retropubic prostatectomy. Nerve sparing prostatectomy was developed to
improve post-operative potency rates. Response to post-operative sildenafil (Viagra) is also improved with this technique. A new
device, the Cavermap, has been developed to permit intraoperative nerve stimulation and localization. Nowadays, laparoscopic
prostatectomy is increasingly used. The factors used in determining patient eligibility for radical prostatectomy are PSA,
stage of disease, age, and wishes of the patient. There still exist controversies for patient selection, partly due to different results
on predictor variables for biochemical disease-free status. The management of D1 (pelvic nodal metastases) patients is
another controversial issue. Nodal cancer volume was the most significant determinant of progression to distant metastasis in
lymph node-positive prostate cancer patients. Messing found an improved survival and reduced risk of recurrence in node
positive patients after radical prostatectomy and pelvic lymphadenectomy when hormonal therapy was started immediately.
The role of radiotherapy and hormonal treatment in combination with surgery is the subject of continuous research. A
number of studies have addressed the value of neoadjuvant hormonal treatment prior to prostatectomy. The majority
employed 2-3 months of total androgen blockade and reported less positive surgical margin, less extracapsular extension,
clinical and pathological downstaging, but no improvement in biochemical progression or survival. After prostatectomy,
patients whose PSA begins to rise after an undetectable level should be referred for salvage treatment with radiotherapy
when their PSA is still less than or equal to 1.0 ng/ml.
Rak prostaty
W pracy omówiono dost´py chirurgiczne stosowane podczas operacji gruczo∏u krokowego. Radykalna prostatektomia mo˝e
byç przeprowadzona zarówno z dost´pu kroczowego, jak i za∏onowego. Kamieniem milowym w poznawaniu anatomii mied-
nicy ma∏ej, a w szczególnoÊci gruczo∏u krokowego i jego bezpoÊredniego sàsiedztwa, stanowi∏y prace Walsha. Odcisn´∏y si´ one
na post´powaniu klinicznym, przyczyniajàc si´ do spopularyzowania radykalnej prostatektomii za∏onowej. Celem ogranicze-
nia pooperacyjnych zaburzeƒ potencji wprowadzono prostatektomi´ oszcz´dzajàcà p´czki naczyniowo-nerwowe; przy tej
technice operowania poprawia si´ odpowiedê na leczenie sildenafilem (Viagra) w okresie pooperacyjnym. Âródoperacyjnà sty-
mulacj´/lokalizacj´ nerwów u∏atwia urzàdzenie zwane „Cavermap”. Ostatnio coraz cz´Êciej wykonuje si´ prostatektomi´ la-
paroskopowà. Podstawowe czynniki brane pod uwag´ podczas kwalifikacji do radykalnej prostatektomii to poziom PSA, sto-
pieƒ zaawansowania choroby, wiek oraz zgoda chorego. Kwalifikacja chorych nadal budzi kontrowersje, g∏ównie z powodu
rozbie˝nych wyników badaƒ biochemicznych, uwa˝anych za czynniki rokownicze prze˝ycia bez choroby. Post´powanie
u chorych z cechà D1 (przerzuty do w´z∏ów ch∏onnych w obr´bie miednicy) jest kolejnym zagadnieniem dyskusyjnym. Obj´-
toÊç mas przerzutowych w w´z∏ach jest najbardziej istotnym czynnikiem w´z∏owym, okreÊlajàcym mo˝liwoÊç progresji o cha-
rakterze odleg∏ych przerzutów. Messing opisuje wyd∏u˝enie prze˝ycia i zmniejszenie ryzyka wznowy u chorych z przerzutami do
w´z∏ów ch∏onnych, u których, bezpoÊrednio po radykalnej prostatektomii i usuni´ciu w´z∏ów ch∏onnych z miednicy, rozpocz´-
to hormonoterapi´ adiuwantowà. Znaczenie radioterapii i leczenia hormonalnego, w po∏àczeniu z leczeniem chirurgicznym
jest przedmiotem intensywnych badaƒ. W kilku spoÊród nich koncentrowano si´ na hormonoterapii neoadiuwantowej
(przed radykalnà prostatektomià), stosujàc zazwyczaj przez 2-3 miesiàce ca∏kowità blokad´ androgenowà. Uzyskiwano
wówczas lepsze wyniki podczas badania marginesów chirurgicznych, rzadziej obserwowano przekraczanie torebki gruczo∏u przez
nowotwór, cz´Êciej natomiast obserwowano „downstaging” – zarówno klinicznie, jak i histopatologicznie. Z drugiej strony nie
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Introduction
Radical prostatectomy is an option for the curative
treatment of organ-confined prostate cancer and
continues to be the mainstay of therapy for localised
prostate carcinoma in the United States [1] where caring
for radical prostatectomy patients accounts for appro-
ximately half of the $1.7 billion annual cost of prostate
carcinoma treatment.
The surgical management of prostate cancer is
a vast topic and this chapter will only review the evolution
of surgical technique, the factors used in patient selection,
and the indications for neoadjuvant and adjuvant therapy.
The determination of lymph node metastases has
important prognostic implications for patients with
suspected organ-confined disease. To date no radiological
investigation, including and bipedal lymphangiography
[2], has been shown to be able to accurately identify
metastatic lymph node involvement pre-operatively.
Prediction of pathological stage, however, can be esti-
mated using preoperative values of PSA, clinical stage,
and Gleason score [3]. In patients at high risk of pelvic
node involvement, staging may be performed by laparo-
scopic pelvic lymph node dissection which is a low
morbidity procedure.
Another option is to assess the nodes at the time of
prostatectomy with intraoperative frozen sections.
Unfortunately though, frozen section diagnosis of
metastatic carcinoma in pelvic lymph nodes has a high
false negative rate and is also costly [4]. Pathological
examination also helps to evaluate the completeness of
lymphadenectomy but anatomical studies investigating
the average number of pelvic lymph nodes are few.
An interesting study is that of standard pelvic
lymphadenectomy performed on 30 human cadavers and
59 consecutive patients with clinically organ confined
prostate cancer during radical retropubic prostatectomy
[5]. The mean number of lymph nodes removed in
autopsy specimens were 22.7 ± 10.2 with a range 8-56,
was nearly identical to that from patients with prostate
cancer, mean of 20.5 ± 6.6 with a range of 10-37,
although striking inter-individual differences were
observed. Patients with prostate cancer demonstrated
enlarged nodes regardless of whether they did or did not
contain tumour. Lymphadenopathy in prostate cancer
patients is not always a result of metastases but can be
due to benign, hyperplastic changes of the nodal tissue.
Surgical Approaches
Pe r i n e a l  v e r s u s  Re t r o p u b i c  A p p r o a c h
Radical prostatectomy can be performed using a perineal
(RPP) or retropubic (RRP) approach [1]. Patients who
underwent RRP had a slightly longer length of hospital
stay, five days with a range of 3-16, versus the RPP
patients, four days with a range of 1-19. Other factors
associated with longer hospital stays were the use of
intraoperative epidural anaesthesia and the increased use
of post-operative narcotics regardless of the surgical
approach. Time to both fluid intake and solid food intake
were significantly longer for patients who underwent the
retropubic approach. As regards prostate cancer cure
rates, RRP and RPP are comparable [6]. The advantages
of RPP in this study included lowered blood loss, easier
post-operative nursing care, lower analgesic use and
earlier discharge from hospital. Using RRP however
affords the ability to perform pelvic node dissection, and
provides better exposure for nerve sparing techniques.
A modified extrafascial RRP technique was
introduced to decrease the frequency of positive surgical
margins in low volume T2 cancers < 2 cm3 [7]. The
anatomical details have been described which are
necessary for exposure of periprostatic fascias and
extrafascial dissection at (1) the prostatourethral junction
which ensures wide excision of the anterior and apical
aspect of the prostate and (2) the posterior and apical
area (development of the prerectal space), and the lateral
and posterior areas at the base of the prostate which
ensures wide excision of the rectoprostatic fascia
(Denonvilliers's fascia) and lateral prostatic fascia [7].
N e r v e  S p a r i n g  P r o s t a t e c t o m y  &  E r e c t i l e
Fu n c t i o n
Because of the significant emotional and lifestyle changes
of impotence, nerve sparing prostatectomy was developed
to improve post-operative potency rates [8]. Erectile
function can be preserved in up to 75% patients if both
cavernous nerves can be spared. Response to post-
operative sildenafil (Viagra) is also improved with this
technique. The cavernous nerves are often difficult to
visualise and may have a variable course but a tumescent
response to nerve stimulation can be consistently
demonstrated. A new device, the Cavermap, has been
developed to permit intraoperative nerve stimulation and
localisation. An initial phase 2 and subsequent phase
3 single blind, randomised, multicentre study that
compared Cavermap assisted prostatectomy with
obserwowano poprawy zarówno w zakresie biochemicznych wyk∏adników progresji, jak i w zakresie d∏ugoÊci prze˝ycia. Pacjen-
ci u których, po radykalnej prostatektomii, poziom PSA zaczyna wzrastaç powy˝ej wartoÊci nieoznaczalnych, powinni byç skie-
rowani celem przeprowadzenia ratujàcej radioterapii, zanim poziom PSA osiàgnie poziom powy˝ej 1 ng/ml.
Key words: prostate cancer, hormone, radiotherapy, surgery
S∏owa kluczowe: rak prostaty, hormony, radioterapia, chirurgia
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conventional nerve sparing has demonstrated a significant
benefit in terms of the duration of nocturnal tumescence
at one year [9, 10]. Other approaches are being explored
to preserve potency, including sural nerve grafting, and
direct corpus cavernosum pressure monitoring during
nerve stimulation [9]. These nerve sparing techniques
may be applied to other oncological surgery such as
cystectomy or abdominal-perineal resection.
U r i n a r y  I n c o n t i n e n c e  A v o i d a n c e
Many modifications in surgical technique have been
developed to avoid urinary incontinence. Initially, creation
of a neobladder neck, bladder neck preservation,
periurethral injection of bulking agents, and anterior
urethropexy were attempted, but with little success. Other
modifications, however, have been more promising.
A technique of nerve dissection used in the
Montefiore/Albert Einstein College of Medicine [11]
starts at the lateral aspect of the prostate with secondary
urethral dissection and limits the dissection around the
striated sphincter. A technique for radical retropubic
prostatectomy that spares the puboprostatic ligaments
and preserves the normal anterior support of the urethra,
has also been described [12, 13]. Careful dissection of
the prostate from the bladder can be performed in such
a manner as to preserve most of the circular fibres of the
bladder neck [14]. This bladder-neck preservation
technique appears to reduce the risk of an anastomotic
stricture and to accelerate the return of urinary con-
tinence. Although the risk of incomplete resection is
a possibility, an analysis of 676 consecutive prostatecto-
mies revealed that only 4.3% of the men had tumour
touching the inked bladder neck margin. Furthermore,
only 1% had this as the only positive margin [14].
In another series, bladder neck preservation was
associated with an increased rate of positive surgical
margins in cancers that had focally penetrated through
the prostatic capsule, stage pT3a. This manifested as
a trend towards decreased PSA-free survival in this group
[15]. In another study, bladder neck preservation did not
shorten the time to achieve urinary continence [8]. A
retrospective study on radical retropubic prostatectomy
examined the merits of bladder neck preservation (101
patients), tennis racket reconstruction (63 patients), and
anterior bladder tube reconstruction (56 patients) [16].
The mean follow-ups were 19.7, 36.7 and 16.2 months
for the three subgroups: overall, bladder neck contracture
occurred in 22/220 cases, including 5% with bladder neck
preservation, 11% with tennis racket reconstruction and
18% with anterior bladder tube reconstruction. This data
approached but did not reach statistical significance, P =
0.061. Urinary continence was assessed by a third party
telephone interview of 165 patients, continence rates at
one year for the three subgroups were 93%, 96% and
97%: not statistically significant, P = 0.68. Positive margin
rates were 27.4% with bladder neck preservation versus
30.5% with excision, which was also not significantly
different [16].
L a p a r o s c o p i c  L y m p h a d e n e c t o m y
Walsh's landmark studies in 1983-84 on pelvic and
prostatic anatomy and the resultant surgical implications
have increased the popularity of radical retropubic
prostatectomy [17, 18]. The perineal approach fell from
favour and few urologists had the opportunity to learn
this operation. With the introduction of the laparoscopic
lymphadenectomy there has been a renewed interest in
the radical perineal prostatectomy [19]. Because of the
improved visualisation, lowered blood loss, and
diminished morbidity the perineal approach has regained
some of its popularity.
Combined prostatectomy and pelvic lymph node
dissection can only be performed using the retropubic
approach. Assessment of nodal status in high-risk patients
can be performed as a separate procedure using
laparoscopic or open techniques. Although the minilap
has been described as a reasonable alternative to laparo-
scopic node dissection [20], the minimally invasive aspect
of the latter technique has made it the treatment of choice
for most urologists.
Transperitoneal laparoscopic radical prostatectomy
has recently been developed as a minimally invasive
approach to surgical treatment of prostate cancer [21].
Using this technique, the posterior aspect of the prostate
is initially mobilised away from the rectum. The retro-
pubic space is then entered by incising the parietal
peritoneum and the apical dissection is performed. Once
the prostate is fully mobilised, it is separated from the
bladder using a bladder neck preserving dissection. The
vesicourethral anastomosis is performed and the prostate
gland removed. The proposed benefits of this minimally
invasive approach are better visualisation deep in the
pelvis, shorter post-operative hospital stays, and less post-
operative pain. Early studies failed to show a decrease
in length of hospital stay (mean hospital stay was 7. 8
days [21]) but nowadays patients are routinely sent home
on the third post-operative day. Early reports described
rectal injuries as intraoperative complications but these
occurred early in the learning curve of the procedure [21,
22]. The mean post-operative bladder catheterisa-
tion time was 6.6 ± 2.4 days [23]. The positive and
questionable surgical margin rate was 15% which is
comparable to open prostatectomy series. Pathological
tumour stage of these margin-positive cases was pT2a in
four specimens (11%), pT2b in 11 (16%), pT3a in 0 and
pT3b in 3 (50%).
In summary, laparoscopic prostatectomy appears to
be a viable surgical option in experienced hands. It is
important to state, however that this technique is
technically demanding and should only be attempted by
those surgeons experienced in laparoscopic surgery. As
long-term data is still lacking, the exact role of laparo-
scopic prostate surgery is as yet undefined. Whether the
longer surgical times and surgical expertise demanded
by laparoscopic surgery will be offset by the potential
benefits will only be determined by further study.
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Ro u t i n e  Pe l v i c  L y m p h a d e n e c t o m y
The need for routine pelvic lymphadenectomy in all
prostatectomy patients has been questioned. Results from
the Mount Zion Cancer Centre, University of San Fran-
cisco, showed that lymph node dissection is unnecessary in
the subset of patients in which the risk of lymph node
involvement is less than 18% [24]. In another study,
575 prostatectomy patients with favourable tumour cha-
racteristics, that is, PSA ≤ 10 ng/ml, Gleason score ≤ 6
or and clinical stage T1 or T2 [25], were divided into two
groups according to whether PLND was performed
(PLND, 372 patients) or omitted (No PLND, 203
patients). Proportional hazards were used to analyze the
effect of age, race, family history, stage, biopsy Gleason
score, initial PSA, PLND, and pathological findings on the
likelihood of biochemical failure. After a mean follow-up
of 38 months, range 1-141, the actuarial four-year
biochemical relapse-free rate for the PLND versus No
PLND groups was 91% versus 97%, P = 0.16. Therefore,
the omission of PLND in patients with favourable tumour
characteristics does not adversely affect biochemical
relapse rates [25].
S e n t i n e l  L y m p h  N o d e  B i o p s y
Finally, it is noted with regard to surgical approaches that
although sentinel lymph node (SLN) biopsy has been
increasingly used in other cancer sites, such as, breast
cancer, penile cancer and melanoma, it has not been
found to be a reliable staging procedure for prostate
cancer [26].
Patient Selection & Predictor Variables for
Biochemical Disease-Free Status
P SA ,  S t a g e ,  A g e  &  Pa t i e n t  P r e f e r e n c e
The factors used in determining patient eligibility for
radical prostatectomy are PSA, stage of disease, age, and
wishes of the patient. In general, radical prostatectomy is
reserved for men with at least a 10 year life expectancy
and therefore patient age and co-morbid disease play an
important part in patient selection. An age of 70 is often
used as the upper limit of surgical consideration but this
should not be viewed as an absolute cut-off value and
selection should be individualised for each patient. In
fact, using Medicare claims data, 29% of the radical
prostatectomies were performed in men ≥ 70 years in 10
hospitals in Kentucky and Indiana [27].
S e r u m  P S A
Although serum PSA can be considered a surrogate for
tumour burden, no threshold value for surgical case
selection has been determined. A total of 7/210 patients
with PSA < 20 ng/ml presented with bone metastases
including 4/7 with a PSA < 10 ng/ml [28]. The highest
preoperative serum PSA was 23 ng/ml among the 181
men biochemically free of disease after prostatectomy
[29]. Only 9/57 (15.8%) men with PSA > 15 ng/ml
remained biochemically free of disease with a greater
than three year follow-up. This study also found that
transition zone cancers had improved disease-free survival
versus peripheral zone disease.
G l e a s o n  S c o r e ,  S e r u m  P S A ,  C a n c e r
Vo l u m e  &  P r o s t a t e  We i g h t
The most important variables found to predict bio-
chemical disease-free status for peripheral zone cancers
were Gleason scores 4 and 5, cancer volume, serum
PSA and prostate weight. Because of poor cure rates, it
has been recommended [30] that men with serum PSA >
15 and perhaps even > 10 ng/ml be considered for
rebiopsy in order to prove a transition zone location or
else therapy other than radical retropubic prostatectomy
should be sought. D'Amico also found that a pre-
operative PSA > 10 ng/ml or a pathological Gleason
score ≥ 7 have significant decrements in short-term PSA
failure-free survival [31]. Positive margin is significantly
more common when PSA > 15 ng/ml (P=0.006), higher
Gleason grade (P=0.01), higher proportion of stage T2b
or T2c (P=0.003) and nodal involvement (P=0.001) [32].
Pe l v i c  L y m p h  N o d e  D i s s e c t i o n
Because of the accuracy in predicting organ confined
disease based on pre-operative factors, pelvic lymph node
dissection need not be performed in every patient. PSA
level < 10 ng/ml and Gleason score < 7 are rarely
associated with nodal involvement and therefore node
dissection may be omitted [25, 33, 34].
Po s i t i v e  P r o s t a t e  N e e d l e  B i o p s y
The percentage of positive cores in prostate needle
biopsy specimens is another pre-operative factor being
studied [35]. It has been found to be a strong predictor of
tumour stage and volume at radical prostatectomy.
Multivariate analysis has showed that the percentage of
positive cores (P=0.0003), initial serum PSA (P=0.005)
and Gleason score in the needle biopsy (P=0.03) were
the only parameters predictive of pathological stage: T2
versus T3.
L o c a l l y  A d v a n c e d  T 3  D i s e a s e
The treatment of locally advanced stage T3 prostate
carcinoma is a dilemma. The reliability of the clinical
assessment of extracapsular extension by digital rectal
examination (DRE) is crucial. Results from series of
patients with T3 prostate cancer treated by radical
prostatectomy indicate that DRE has shown a wide range
of accuracy ranging from 44% to 82%. The assessment of
capsule perforation on biopsy provides a 96% specificity
rate and a positive predictive value of 60% [36]. Infor-
mation regarding the correlation between T3 clinical
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staging and conventional/endorectal coil MR imaging
staging is still needed.
The accuracy rate of DRE for T3 staging increases to
more than 90% if the PSA level is > 15 ng/ml: although
31% of T3 patients had node-positive disease, 25% were
pathologically organ-confined tumours that had been
clinically overstaged. Cancer-specific survival rates at five,
10, and 15 years were respectively 93%, 84%, and 74%,
and operative morbidity paralleled that of patients with
clinically localized disease [37].
In conclusion, preoperative factors including PSA
should be carefully considered in clinically advanced
disease. Surgical treatment of T3 disease still affords long-
term survival with low treatment-related morbidity and
can be supplemented with adjuvant therapy. Clinical T3
disease should thus not be considered an absolute
contraindication to radical prostatectomy.
Pe l v i c  N o d a l  M e t a s t a s e s ,  S t a g e  D 1
The management of D1 (pelvic nodal metastases) patients
is another controversial issue. Nodal cancer volume was
the most significant determinant of progression to distant
metastasis in lymph node-positive prostate cancer patients
[38]. Messing found an improved survival and reduced
risk of recurrence in node positive patients after radical
prostatectomy and pelvic lymphadenectomy when
hormonal therapy was started immediately [39].
Progression-free survival was also found to be increased in
D1 patients after radical prostatectomy versus those
receiving radiotherapy or conservative therapy, P=0.055
[40].
Although pre-operative nodal involvement is
considered an absolute contraindication to radical
prostatectomy Frohmuller contested this idea [41]. His
series of 139 patients with histologically proven stage D1
(T1-T3 pN1-2 M0) consisted of 87 patients followed by
androgen deprivation alone (group 1) and 52 patients
with additional radical prostatectomy (group 2). The
actuarial 10-year non-progression rates were 14.6% in
group 1 and 35.8% in group 2, P=0.0016. The overall
and disease-specific 10-year survival rates were found to
be 29.7% and 32.1% for group 1 and 50.8% and 70.7%
for group 2. Local progression as the main parameter
influencing quality of life occurred in 60/87 patients (69%)
not subjected to radical prostatectomy. Transurethral
resection of the prostate was required in 29 of these
patients. In contrast, following radical prostatectomy,
only 4 /52 patients (8%) had local progression and only
one patient required a dilatation of the vesicourethral
anastomosis for relief of infravesical obstruction.
Thus, radical prostatectomy plus androgen de-
privation for patients with stage D1 prostate cancer
appeared to be superior to androgen deprivation alone
with respect to survival expectancy and quality of life [41].
Only high Gleason scores, 8 to 10, on the pre-operative
biopsy was found to correlate with rapid progression to
distant metastases (P ≤ 0.00001) in a multivariate analysis
[30]. If the Gleason score was < 8, the likelihood of
distant metastases was only 18% and 41% at five and 10
years, whereas 85% of men with a Gleason score of 8, 9 or
10 had distant metastases by five years.
For urologists who believe that radical prostatectomy
is useful in providing local control in men with positive
lymph nodes, frozen section analysis of lymph nodes is
probably not necessary in men who have pre-operative
Gleason scores of < 8. Conversely, in patients with
a Gleason score of 8 to 10 on needle biopsy, careful
analysis of lymph nodes is necessary to avoid radical
prostatectomy in those who will derive little benefit [30].
Pa t i e n t ' s  Vi e w p o i n t
Apart from the above objective selection considerations,
the wishes of patient and family also need to be taken
into account. Urinary incontinence following radical
prostatectomy has a significant deleterious effect on
quality of life and, unfortunately, is much more prevalent
following surgery compared with other treatment moda-
lities, such as radiation therapy. Alternative modalities
of treatment should be carefully discussed with the patient
and family so as to allow them to make an informed
decision suited to their expectations.
Assessment of Prognostic Indicators
H o s t  &  Tu m o u r  Fa c t o r s
Prognostic indicators can be divided into host (for
example, age & race) and tumour factors (for example,
Gleason grade & clinical stage) but sometimes they are to
a certain extent inter-related. For instance, African
Americans are less likely than Caucasians to receive PSA
screening and may present at a later stage. However,
given the same stage, preoperative PSA, Gleason score, in
an equal access medical care facility, race was not an
independent factor of biochemical recurrence in post-
prostatectomy patients [42,43]. Similarly, other studies
also reported that race does not appear to adversely affect
biochemical disease-free survival in males treated for
early stage prostate cancer. African-American males with
early stage prostate cancer should expect similar
biochemical disease-free survival rates to those seen in
Caucasian males [44].
C a P S U R E  S t u d y
A report from the University of California, for a series of
1383 patients enrolled in the Cancer of the Prostate
Strategic Urologic Research Endeavor (CaPSURE),
a longitudinal registry of patients with prostate cancer,
who underwent radical prostatectomy, stated that more
complete pathological analysis of the prostatectomy
specimen predicts outcome more accurately [45].
Specimens were considered step-sectioned only if the
entire specimen was submitted for analysis and if sections
were taken at 5 mm intervals or less. Patients with
negative margins in whom step-sectioning was performed
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exhibited significantly lower secondary non-adjuvant
treatment use and appeared to have a lower risk of PSA
recurrence than similar patients in the non-step-sectioned
group [45]. Early biochemical recurrence was associated
with other prognostic indicators including pre-operative
PSA, tumour volume, Gleason score, clinical stage,
surgical margin positivity, periprostatic tissue involvement,
capsular invasion and seminal vesicle invasion [46].
S e m i n a l  Ve s i c l e  I n v o l v e m e n t
Involvement of seminal vesicle is generally believed to
herald distant metastases. TRUS guided seminal vesicle
biopsy is useful and reliable for pre-operative staging and
helpful in correct decision making for prostatectomy [47].
The use of the endorectal coil MR imaging data provides
a more accurate prediction of the pathological outcome of
seminal vesicle invasion [48]. Epstein and Walsh reported
a few patients with node-negative, seminal vesicle-positive
tumours who had an excellent long-term prognosis. Most
of these patients can be split into two groups, one
experiencing rapid and the other slower progression [49].
Pe r i n e u r a l  I n v a s i o n
Perineural invasion on preoperative prostate needle
biopsy is a strong independent predictor of PSA re-
currence in patients in whom prostate cancer was treated
with radical prostatectomy [50]. However, when
perineural invasion was compared with other post-
operative parameters, including disease stage, surgical
margins and seminal vesicle invasion, it was not an
independent predictor because it closely correlated with
tumour stage.
N e w  P r o g n o s t i c  I n d i c a t o r s
Newer prognostic indicators are being investigated,
including. tumour angiogenesis, Ki 67 labelling index and
reverse transcriptase-polymerase chain reaction (RT-
PCR) [51, 52]. Tumour angiogenesis as measured by
microvessel density is associated with a negative clinical
prognosis after radical prostatectomy [52]. A tumour cell
proliferation marker: Ki 67 labelling index, is an
independent predictor of tumour progression [51].
The RT-PCR assay for PSA can detect circulating
prostate cells. It is the best predictor of potential surgical
failures; 70% of patients with positive surgical margins
or invasion into the seminal vesicle were identified pre-
operatively by a positive RT-PCR assay (odds ratio = 12.0,
positive predictive value = 64%, negative predictive
value = 87%) [53]. RT-PCR was able to pre-operatively
identify patients with adverse pathology, despite low
serum PSA values of < 4.0 ng/ml. In patients with high
PSA level, of > 10 ng/ml, RT-PCR discriminated between
potentially curable candidates and those with established
extraprostatic disease. Despite these impressive results,
the final role for the RT-PCR assay is as yet undefined
partly due to the high cost and limited availability of this
technique.
U l t r a s e n s i t i v e  P S A  A s s a y  &  M R  I m a g i n g
Recent developments to detect recurrence include
ultrasensitive PSA assay and MR imaging. Although
the definition of biochemical recurrence is not abso-
lutely defined, traditionally a post-operative PSA level
> 0.2 ng/ml has often been used. With the advent of the
ultrasensitive PSA assay, biochemical recurrence can be
detected earlier. In one study, the ultrasensitive assay
was found to detect recurrence by an average of 18
months earlier than the conventional PSA method [46].
PSA by ultrasensitive assay > 0.1 ng/ml is generally
indicative of post-operative failures. MR imaging findings
of definite extracapsular spread of disease helped to
predict prostate tumour recurrence with high specificity,
although with low sensitivity [54].
T i m i n g  o f  Po s t - P r o s t a t e c t o m y  Fa i l u r e
The timing of failure after prostatectomy has been studied
in detail. Of the peripheral zone failures, 60% occurred in
the first year after radical retropubic prostatectomy and
95% had occurred by the end of the fourth year [29].
Annual hazard rates for progression were highest during
the first two years after radical prostatectomy for the
entire population [55]. Patients with adverse prognostic
features (that is, pT3b, PSA ≥ 10 ng/ml, Gleason score 8-
10 and nondiploid cancers) had high initial hazard rates
that decreased with time to lower levels. Those with
pathologically organ-confined cancer had low but constant
hazard rates throughout follow-up. Progression after
radical prostatectomy usually occurs early reflecting the
impact of clinical understaging. However a significant
number of men, including those with organ confined
cancers, will continue to have disease progression after
five years. Patients undergoing radical prostatectomy
should be subjected to long-term follow-up to allow the
option of early intervention should progression occur
[55].
Outcome: Radical Prostatectomy versus
Radiotherapy
Martinez has compared the results of radical prosta-
tectomy with pelvic lymph node dissection to external
radiotherapy. For patients with pretreatment PSA levels ≤
10 ng/ml and Gleason scores ≤ 6, conventional doses
of external beam radiotherapy (median 66.6 Gy, range
59.2-70.2 Gy) and radical retropubic prostatectomy
achieved similar seven-year rates of biochemical control
and cause-specific survival, which were unaffected by age
at diagnosis [56]. However for organ-confined prostate
cancer as a whole, Paulson reviewed the randomised and
non-randomised studies, and concluded that radical
prostatectomy provides a significantly better outcome
than does external beam radiotherapy [2, 57, 58].
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A quality of life comparison of radical prostatectomy
and interstitial brachytherapy in the treatment of clinically
localised prostate cancer was reported by Krupski [59].
The primary outcome measures were the Functional
Assessment of Cancer Therapy scale (FACT-G), Ame-
rican Urological Association (AUA) International Prosta-
te Symptom Score (IPSS), Urinary Function Questionnaire
for Men after Radical Prostatectomy and Brief Sexual
Function Inventory [59]. Data from 138 patients were
included in the analysis; 27 had radical prostatectomy
(RP), 70 had brachytherapy monotherapy (BTM) of 115
Gy or combined brachytherapy (90 Gy) and external
beam radiation (40-45 Gy) (BTC).
Correlations were noted between total FACT-G and
urinary symptom score, degree of sexual function,
frequency of diarrhoea, and frequency of hot flashes.
Problems of urinary function correlated with the degree
of urinary control. The radical prostatectomy and BTM
groups had improvement in quality of life, voiding,
diarrhoea, and sexual function with time, whereas the
BTC group experienced a decline.
The Cancer of the Prostate Strategic Urologic
Research Endeavour (CaPSURE), also examined
potency. Patients undergoing external beam radiotherapy
or radical prostatectomy with or without nerve sparing
all showed comparable rates of improvement in sexual
function during the first year after treatment for early-
stage prostate cancer. However, in the second year after
treatment, patients treated with radiotherapy began to
show declining sexual function, whereas patients treated
with radical prostatectomy did not [60].
Treatment Morbidity after Prostatectomy
Table I shows the acute and chronic complications which
can occur following prostatectomy and their incidence. In
a large review of surgical patients, post-operative com-
plications occurred in 10% of patients overall and were
associated with older age, P < 0.002. The incidence of
complications however declined significantly with
increasing experience of the surgeon, P <0.0001 [61].
Table I. Incidence of acute and chronic post-prostatectomy
complications [62, 63]
Acute complication Incidence (%)
Intraoperative bleeding 3.5
Post-operative bleeding 2
Impotence 22-95
Incontinence < 5 – 27
Ureteral injury < 1
Urinary fistula 1-2
Perforation of rectum < 1
Mortality 1
Chronic complication Incidence (%)
Urinary incontinence 8
Impotence 13
Bladder neck contractures 1-2
U r i n a r y  I n c o n t i n e n c e
The overall incidence of urinary incontinence is higher
than 2% regardless whether the surgical approach is
retropubic or perineal [64]. The median time to
continence recovery, based on the patient self-reporting,
was significantly shorter in the nerve sparing than in the
non-nerve sparing group when continence was defined
as no urinary leakage: 5.3 months versus 10.9 months,
P < 0.01. The nerve sparing technique of radical prosta-
tectomy was associated with improved recovery of urinary
continence in an age dependent manner. Patient age and
the definition of incontinence may partially explain the
variation of continence rates in the literature [8]. Pelvic
floor education was found in a randomised controlled
trial to be very effective to shorten the duration and
improve the degree of incontinence after radical
prostatectomy [65,66].
The morbidity associated with prostatectomy is
variable and is affected by surgeon experience.
Complications from large centres specializing in surgical
treatment are low but nationwide surveys have reported
a much higher risk of complications. Walsh reported
outcomes of 62 men who underwent radical retropubic
prostatectomy at the Johns Hopkins Hospital [63, 67].
By 18 months 93% of the patients were dry, that is,
wearing no pads, and 93-98% characterised urinary
problems as either none or small.
I m p o t e n c e
The other important morbidity of prostatectomy is
impotence. Involuntary loss of urine at orgasm may be the
sufficient reason to avoid any sexual contact with their
partner [68]. Pre-operative potency is definitely known
to be associated with a better response to post-operative
medical treatments with oral, intraurethral, or intracor-
porally injected agents [69]. Early institution of medical
therapy with intracorporal injections starting two months
post-operatively has resulted in a higher incidence of
spontaneous return of erections at one year.
Vacuum erection devices may be successful in
restoring erections but extensive practice in their use is
necessary, and they may be unappealing to many patients.
A penile prosthesis will allow intercourse but is not
commonly chosen in this older population. Prostheses
are expensive and require invasive surgery, but satisfaction
rates among patients and partners who have used them
have been surprisingly high.
In the Johns Hopkins study [63, 67] it was reported
that potency, defined as the ability to achieve unassisted
intercourse with or without the use of sildenafil, improved
gradually and that by 18 months 86% of the patients were
potent and 84% considered their degree of sexual
problems as either none or small.
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M e d i c a r e  &  O t h e r  Po p u l a t i o n - B a s e d
S t u d i e s
In another study, patients who underwent RRP in the
Medicare population [62] were identified by all inpatient,
outpatient, and physician Medicare claims for these men.
Procedures performed for complications resulting from
RRP were recorded, as were the diagnostic codes that
may have heralded a complication after RRP. In 1991
a total of 25,651 men in the Medicare population
underwent RRP: their mean age was 70.5 years. Pro-
cedures for the relief of bladder outlet obstruction or
urethral strictures after RRP occurred in 19.5% of these
men. A penile prosthesis was implanted in 718 men
(2.8%) after prostatectomy, and 593 men (2.3%) had an
artificial urinary sphincter placed after prostatectomy.
A diagnosis of urinary incontinence was reported in 5573
men (21.7%) after radical prostatectomy, but only 2025 of
these men (7.9%) continued to carry this diagnosis more
than one year after prostatectomy. A diagnosis of erectile
dysfunction was reported in 5510 men (21.5%) after
radical prostatectomy, but only 3276 of these men
(12.8%) continued to carry this diagnosis at more than
one year post-surgery [62].
In another population based longitudinal cohort
study, involving a total of 1291 patients, analysis at ≥ 18
months following radical prostatectomy, 8.4% of men
were incontinent and 59.9% were impotent [70]. Among
men who were potent before surgery, the proportion of
men reporting impotence at 18 or more months after
surgery varied according to whether the procedure was
nerve sparing: 65.6% of non-nerve-sparing, 58.6% of
unilateral, and 56.0% of bilateral nerve-sparing.
Sexual performance was assessed as a moderate-to-
large problem in 41.9% of patients. Both sexual and
urinary function varied by age, 39.0% of men aged < 60
years versus 15.3%-21.7% of older men were potent at
≥ 18 months, P < 0.001; 13.8% of men aged 75-79 years
versus 0.7%-3.6% of younger men experienced the highest
level of incontinence at ≥ 18 months, P = 0.03. Sexual
function also varied by race, 38.4% of black males
reported firm erections at ≥ 18 months versus 25.9% of
Hispanic males and 21.3% of white males, P = 0.001.
Pa t i e n t  S e l f - Re p o r t i n g  o f  C o m p l i c a t i o n s
The patient self-reported incidence of any degree of post-
prostatectomy incontinence, impotence and bladder neck
contracture or urethral stricture is generally higher than
surgeons' reported rates. In a multicentre patient self-
reported questionnaire on incontinence, impotence and
bladder neck contracture or urethral stricture, the rates
were respectively 65.6%, 88.4% and 20.5% [36]. The
incidence of incontinence requiring protection was 33%
and only 2.8% of respondents had persistent bladder neck
contracture or urethral stricture.
Although incontinence and impotence significantly
affected self-reported sexual function satisfaction, and
quality of life, P = 0.001, 77.5% of patients responded
that they would elect surgery again. This finding remained
true even after adjusting by multiple logistic regression for
demographic variables, and the time between surgery and
the survey.
Treatment Costs
Radical prostatectomy accounts for approximately half
of the $1.7 billion annual cost of prostate carcinoma
treatment in the United States [1]. The total relative
perioperative cost for transperineal brachytherapy with
125I seeds exceeded that for RRP by 85-105% [71]. The
technical costs included those incurred for anaesthesio-
logy, laboratory medicine, medicine, pharmacy, nursing,
radiology, 125I seeds and brachytherapy. Professional costs
included fees from anaesthesiology, laboratory medicine,
medicine, urology, radiation oncology and physics.
Technical cost, exclusive of 125I seeds, was substantially
lower for transperineal brachytherapy (relative to
prostatectomy cost 0.36-0.42) but was more than offset by
the cost of the 125I seeds when comparing total cost with
radical prostatectomy using a perineal approach (RRP).
Not much work has been undertaken in the cost-
effectiveness of 103Pd seeds, but we know that they are
more expensive than 125I seeds.
Role of Neoadjuvant & Adjuvant Hormonal
Treatment
A number of studies have addressed the value of
neoadjuvant hormonal treatment prior to prostatectomy
[72]. The majority employed 2-3 months of total androgen
blockade and reported less positive surgical margin, less
extracapsular extension, clinical and pathological
downstaging, but no improvement in biochemical pro-
gression or survival [73-78]. Surgical margins were less
often positive in the hormonal therapy (25%) than the
prostatectomy alone (47%) group, P = 0.0001 [76]. The
downstaging suggests the possibility of an improvement in
the morbidity from prostate cancer if post-operative
radiotherapy is not required. No difference in risk of PSA
failure was observed overall between the hormonal
therapy and prostatectomy only groups: hazards ratio
0.94, 95% CI 0.68-1.30.
Treatments with antiandrogen alone for any du-
ration, and those combining antiandrogen and luteinis-
ing hormone-releasing hormone analogue for (3 months
were not associated with improved survival. However,
patients receiving combined therapy for ≤ 3 months had
a significantly lower risk of PSA failure than those treated
with radical prostatectomy alone: hazards ratio 0.52, 95%
CI 0.29-0.93. Prolonged neoadjuvant hormonal therapy
combining antiandrogen and luteinizing hormone-
releasing hormone analogue may improve disease-free
survival after radical prostatectomy [76].
In a study from Vancouver, neoadjuvant hormone
therapy prior to radical prostatectomy was given for eight
months to 156 patients [79] and it was found that the risk
of PSA is low after five years of follow-up. The duration
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of neoadjuvant hormonal therapy needed for beneficial
effect has not yet been determined. More supporting
evidence for a longer duration of hormonal therapy
comes from Norway, CT and MR serial examinations
suggest that neoadjuvant androgen deprivation before
local treatment should last at least six months in order to
achieve a maximal effect in the majority of the patients
[80]. The Canadian Urologic Oncology Group (CUOG) is
presently performing a randomised trial of 3 months
versus 8 months of neoadjuvant androgen deprivation.
The possible theories which might explain the lack of
survival benefit from neoadjuvant hormonal therapy
include the emergence of a hormone resistant tumour
clone, development of a tumour clone that more readily
metastasises, the difficulty of the pathologists to identify
minimal residual disease at the margin after cytoreductive
hormonal treatment, and a rebound phenomenon of
testosterone after cessation of hormonal therapy. The
latter has not been observed in studies of intermittent
hormonal therapy [81].
Based on the data available, neoadjuvant hormonal
treatment prior to surgery would appear appropriate for
those patients at high risk of having a positive surgical
margin [82]. Currently, the LH-RH agonists are the drugs
of choice for adjuvant therapy, whereas combined
androgen blockade has generally been used as neo-
adjuvant therapy [77].
When to Prescribe Adjuvant Radiotherapy
Many authors, particularly in Europe, consider that only
clinical recurrences warrant additional treatment, usually
in the form of radiation therapy [83]. At the time of
clinical recurrence, imaging studies should be performed
to confirm the absence of metastases. Another valuable
tool in determining tumour burden (and indirectly
metastatic disease) is the evaluation of PSA kinetics (PSA
velocity or post-operative doubling time). If the
recurrence seems local, radiation therapy alone is the
best initial option, since concomitant hormone therapy
leads to a decrease in PSA levels even in the presence
of metastatic disease, thus depriving the patient and
physician of a valuable test for monitoring treatment
response.
Increasing evidence points to the advisability of early
radiotherapy for patients with high risk of recurrence
after prostatectomy [84]. Widely quoted studies include
review of 368 total patients, (the numbers of patients in
the various studies are as follows: Forman, 47; Vincini, 68;
Morris, 88; Peschel, 52; Schild, 46; Wu, 53; and Wilder,
14) and all point towards the value of early adjuvant
radiotherapy [85-91].
Acute toxicity from Wilder's study [90] was mild and
did not require medication: Radiation Therapy Oncology
Group grade I. A total of 4/14 patients experienced
genitourinary morbidity and 3/14 experienced gastro-
intestinal morbidity [90]. With regard to late toxicity, 1/14
developed a urethral stricture requiring dilatation:
Radiation Therapy Oncology Group grade III. All 5/14
patients who were potent at the start of radiotherapy
remained potent. Forman's study from the Detroit
Medical Centre reported a chronic complication rate of
17% [85]. In terms of cost, Medicare's median reim-
bursement for salvage 3D conformal radiotherapy in
Wilder's study ($7,512 in 1999 U.S. dollars) is equivalent
to its reimbursement for a 17-month course of goserelin
hormonal therapy [90].
In conclusion, current evidence suggests that post-
prostatectomy patients whose PSA begins to rise after
an undetectable level should be referred for salvage
treatment with radiotherapy when their PSA is still less
than or equal to 1.0 ng/ml. It is also noted that Peschel
reported that the three-year biochemical no evidence of
disease (bNED) survival rate for the adjuvant radiation
group was 85% compared with 27% for salvage radiation
and 43% for the observation group [87]. These results
are statistically significant. Factors that predict bio-
chemical failure following post-operative radiation
therapy include pre-operative PSA level, pre-radiation
therapy PSA level, and seminal vesicle involvement.
Summarising the results in the literature, Grossfeld
constructed a decision tree model of the management of
a positive surgical margin after radical prostatectomy
[92]. The conclusion was that immediate radiation may be
appropriate for patients with positive surgical margins
and a high likelihood of recurrent local rather than distant
disease [31, 92, 93].
Not all reports in the literature are specific
concerning the percentage of cases with single or multiple
positive margins. The Mayo clinic performed a retro-
spective case-matched study of 152 patients to assess the
benefit of adjuvant radiation therapy for localised prostate
cancer with a single positive surgical margin [94]. They
studied the records of a nested matched cohort of 76
patients with pathological stage T2N0 prostate cancer
and a single positive margin who underwent adjuvant
radiation therapy within three months of radical prosta-
tectomy. These patients were matched 1:1 with 76 con-
trols who did not receive adjuvant radiation therapy.
Neither group received androgen deprivation therapy.
Patients and controls were matched exactly for the
margin positive site, age at surgery, preoperative serum
prostate specific antigen, Gleason score and DNA ploidy.
Biochemical relapse was defined as post-treatment PSA
> 0.2 ng/ml. No patient who received radiation therapy
had local or distant recurrence, while 16% of controls
had recurrence, P = 0.015. The estimated improvement in
five-year clinical and biochemical progression-free survival
was significant with 88% ± 5% versus 59% ± 11% of
patients treated with adjuvant radiation therapy versus
no radiation therapy, P = 0.005.
The treatment outcome of radiotherapy after radical
prostatectomy is encouraging [95]. Patients who received
radiotherapy (RT) with a pre-RT PSA < 1.0 ng/ml
demonstrated a progression-free outcome equivalent
to those who received adjuvant RT. Two distinct patterns
of PSA failure were observed on the basis of PSA
nadir after RT. Patients whose PSA failed to reach
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a nadir < 0.2 ng/ml after RT had progression with a high
PSA velocity (1.5 ng/ml/yr). Patients whose PSA reached
a nadir < 0.2 ng/mL but who subsequently had treatment
failure progressed later with a lower PSA velocity (0.36
ng/ml/yr) [95].
Currently the Radiation Therapy Oncology Group is
enrolling high risk pT3N0 patients after prostatectomy
for adjuvant therapy: RTOG P-0011. The three arms are:
(1) LH-RH agonist for 2 years plus radiation therapy
to 63-66.6 Gy; (2) radiation therapy to 63-66.6 Gy; (3)
LH-RH agonist for 2 years. Results from this trial would
be very useful. Arm 3 was closed due to poor accrual
recently.
Role of Surgery after Radiation for Residual or
Recurrent Disease
The role of salvage prostatectomy in this situation
remains unclear. Recurrent prostate cancer after radiation
therapy is in many cases biologically aggressive. It is
unclear whether the biological aggressiveness of radio-
recurrent prostate cancer is due to time-dependent cancer
clonal evolution, potentially induced by radiation damage,
or is due to an innately aggressive tumour secondary to
overexpression or mutation of apoptotic inhibitors that
render these tumours resistant to radiation [96].
Surgery is not often used for salvage of residual or
recurrent disease after radiation due to unacceptable
morbidity. In an effort to decrease morbidity, the M.D.
Anderson Cancer Centre reported on 13 patients with
biopsy proven, locally recurrent prostate cancer after
radiation therapy, who underwent salvage prostatectomy
with complete bladder neck closure and reconstruction
with an appendicovesicostomy to the native bladder in
9/14 and ileovesicostomy in 4/14 [97]. There were no
intraoperative complications. Four patients had serious
complications necessitating reoperation, including
a vesicourethral fistula requiring delayed cystectomy,
wound dehiscence with disruption of the appendicovesical
anastomosis, leakage from the small bowel anastomosis
that resulted in sepsis and death, and stomal stenosis
requiring delayed stomal revision. Of 12 patients two
used pads for incontinence, while 10/12 were dry during
the day and night with a catheterisation interval of 2-6
hours. The post-operative continence rate is excellent
and appears superior to those in the literature for salvage
prostatectomy and vesicourethral anastomosis.
Cryotherapy
Cryotherapy is another treatment option for primary
disease, local residual or recurrent prostate cancer after
radiotherapy, although experience is still limited. Future
efforts designed to improve the current technique should
be encouraged. Longer follow-up results will be available
in the future [98].
Conclusions
Radical prostatectomy is a valid treatment option for
localised prostate cancer and results in excellent long-
term survival. With the evolution of surgical techniques,
morbidity has decreased to acceptable levels. Research on
pre-operative staging tests, newer minimally invasive
techniques, and neoadjuvant/adjuvant therapy will likely
improve on current biochemical recurrence free survival
rates in the future.
Patricia Tai MD
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Allan Blair Cancer Center
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